Apple SVP Sells $15.4M in Shares Following RSU Vesting
Deirdre O’Brien, Senior Vice President at Apple Inc., recently sold shares worth approximately $15.4 million following the vesting of restricted stock units (RSUs). The transactions took place on October 2, 2026, under a pre-arranged Rule 10b5-1 trading plan. O’Brien sold a total of 46,389 shares in two separate transactions, with the first involving 40,764 shares at a weighted average price of $333.35 per share and the second involving 5,625 shares at $333.91 per share. The total value of these sales amounted to $15,466,923.
These sales followed the settlement of 99,878 RSUs into common stock on October 1, 2026. The vesting of these performance-based units was tied to Apple’s total shareholder return (TSR) performance over a three-year period ending with the last day of Apple’s fiscal year 2026. Apple’s TSR of 90.67% ranked in the 76.20th percentile, which triggered the vesting. Additionally, Apple withheld 53,489 shares of common stock at $330.32 per share to cover tax withholding requirements related to the RSU vesting, totaling $17,668,486.
In other recent news, Apple Inc. is facing a mix of developments that could impact investor sentiment. Morgan Stanley adjusted its price target for Apple, lowering it from $360 to $355 while maintaining an Overweight rating. The firm cited limited upside despite an exciting product roadmap. In contrast, Needham reiterated a Hold rating on Apple, highlighting competitive risks from other companies that could challenge Apple’s ecosystem. Meanwhile, Morgan Stanley remains optimistic about iPhone 18 demand, noting steady lead times that suggest robust initial interest.
Apple, along with another company, is also facing a consumer class action in the UK related to a 2018 sales agreement on Amazon’s UK marketplace. The UK’s Competition Appeal Tribunal has allowed the class action to proceed for purchases made on Amazon’s UK store. In broader market news, Bank of America has shifted its stance, downgrading Industrials while upgrading Healthcare stocks, indicating a strategic reallocation in investment focus.